Bladder cancer immunotherapy cuts tumor recurrence risk by 68%
โฎ BeforeBladder cancer tumors often return after treatment.
โ
NowAn immunotherapy from CG Oncology reduced that risk by 68 percent in reported results.
In short
- CG Oncology's bladder cancer immunotherapy reduced the risk of tumor recurrence by 68%.
- The results may change how physicians treat certain patients.
- The source gives no trial size or stage details.
Why it's good news
Recurrence is one of the hardest parts of bladder cancer to manage, because patients need repeated monitoring and procedures. A 68 percent reduction in risk, if it holds, would change treatment choices for some patients. The source is brief, so the size of the study and its stage should be checked in the full report.
Advertisement
From STAT
CG Oncology's bladder cancer immunotherapy reduced risk of tumor recurrence by 68% โ results that may change how physicians treat certain patients.
Ask this story
Next in today's ten
Advertisement